When does the linagliptin patent expire (and what does “run out” mean)?
You’re likely asking about the end of legal exclusivity that blocks generic manufacturers. “Patent run out” can mean different timelines depending on the jurisdiction and the type of protection involved (e.g., a formulation patent vs. method-of-use), and on whether regulators grant additional exclusivity beyond basic patents.
Can the exact expiry date be given from the provided information?
I can’t provide a specific expiry date for linagliptin from the information available here. Patent expiry dates require a source that lists the relevant patents (by country and patent number) and their application/grant/term details.
What’s the fastest way to get the correct expiry date for your country?
Search for the expiry using one of these approaches for the jurisdiction you care about:
- The relevant “linagliptin” patent list in that country’s patent database (often by compound name and key assignees).
- The drug’s regulator-linked “exclusivity” or “patent status” page (which usually summarizes which protections still block generics).
- A commercial patent landscape for “linagliptin” tied to your market.
If you tell me the country, can I narrow it to a likely expiry?
Yes. Reply with the country (e.g., US, UK, EU/EMA member state, Canada, Australia, India) and whether you mean:
- patent expiry only, or
- marketing exclusivity / patent-linked exclusivity that affects generic entry.
Then I can target the correct type of protection and the right market-specific timeline.
Sources
None cited (no patent/exclusivity source content was provided in the prompt).